ArticleNature communications2025
Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dynamic DNA Nanomachines for Biosensing and Drug Delivery.Sensors (Basel, Switzerland) · 2026Review
- DNA Nanostructures for siRNA Delivery.Bioconjugate chemistry · 2026Review
- Targeting the APE1 hub: integrating DNA repair and redox signaling for precision management of inflammation-associated diseases.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Small interfering RNAs (siRNAs) have emerged as versatile therapeutic agents for ulcerative colitis, and approaches to optimize their assembly, delivery, and on-demand release are therefore needed. Here, we present a method for the precise assembly and accurate dosing of two types of siRNAs on an enzyme-triggerable DNA origami nanodevice. We design a DNA duplex structure as an inflammation-responsive switch and demonstrate that the nanodevice accumulates autonomously and predominantly in the intestine and selectively exposes siRNAs through a translocated enzyme in inflammatory cells. We find that this strategy can effectively inhibit multiple pathogenic genes and pathways in inflamed cells, while remaining inert in healthy cells. We show that when administered to mice with DSS-induced colitis, the nanodevice increases survival rates up to 100% and exhibits robust therapeutic efficacy and biosafety. This study demonstrates that the nanodevice can serve as a switchable delivery platform for siRNA specifically targeted to the intestine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.